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Abstract 
Background 
Timely diagnosis and treatment of latent tuberculosis infection (LTBI) through screening remains a 
key public health priority. Although globally it is recommended to screen people at high risk of 
developing TB, the economic evidence underpinning these recommendations is limited. This review 
critically appraised studies that had used a decision-analytical modelling framework to estimate the 
cost-effectiveness of interferon gamma release assays (IGRAs) compared to tuberculin skin test (TST) 
for detecting LTBI in high risk populations.  
 
Methods 
A comprehensive search of MEDLINE, EMBASE, NHS-EED was undertaken from 2009 up to June 
2015. Studies were screened and extracted by independent reviewers.  The study quality was assessed 
using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and the Philips’ 
checklist, respectively. A narrative synthesis of the included studies was undertaken. 
 
Results  
Ten of 8793 studies were considered relevant for inclusion. Two economic evaluations were 
conducted in a child population, six in an immunocompromised population and two in a recently 
arrived population.  Most studies (n=7) used a decision tree structure with Markov nodes. In general, 
all models performed well in terms of reporting quality, but were subject to limitations to structure 
and model inputs.  Models have not elaborated on their setting or the perspective of the studies was 
not consistent with their analyses. Other concerns were related to derivation of prevalence, test 
accuracy and transition probabilities. 
 
Conclusion 
Current methods available highlight limitations in the clinical effectiveness literature, model 
structures and assumptions, which impact on the robustness of the cost-effectiveness results. These 
models available are useful, but limited on the information that can be used to inform on future cost-
effectiveness analysis. Until consideration is given on deriving the performance of tests used to 
identify LTBI that progresses to active TB, and the development of more comprehensive models, the 
economic benefit of LTBI testing with TST/IGRAs in high risk populations will remain unanswered. 
 
Keywords: Systematic review, latent tuberculosis, decision-analytical modelling, cost-effectiveness  
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Background 
 
Diagnosis and treatment of latent Tuberculosis infection (LTBI) through screening remains a key 
public health priority in the elimination of tuberculosis. For over a century, the tuberculin skin test 
(TST) has been used to diagnose LTBI, despite its many limitations. These include being neither very 
sensitive, due to anergy in an immunocompromised population, nor specific, due to cross-reactivity in 
people who are Bacilli Calmette-Guérin (BCG) vaccinated and those who are infected with non-
tubercular mycobacteria (NTM).[1] Furthermore, TST requires people to return to have their results 
read, and there is the possibility of error when measuring the size of the induration of the skin 
reaction. This has led to the development of new in vitro interferon-gamma release assays (IGRAs) 
aimed at improving the diagnosis for LTBI.  
 
Currently, two IGRAs are commercially available for the diagnosis of LTBI, QuantiFERON Gold In-
tube (QFT-GIT) (Cellestis Ltd., Carnegie, Australia) and T-SPOT.TB (Oxford Immunotec Ltd, 
Oxford, UK). IGRAs do not boost responses due to repeated testing, and people are not required to 
make a second visit to have the results read.[2] These tests offer alternatives for the diagnosis of 
LTBI, but are more expensive. In the UK, current guidelines recommend the use of IGRAs and/or 
TST for the diagnosis of LTBI in high risk populations which include children, people who are 
immunocompromised or at risk of immunosuppression and people from countries with a high 
incidence of TB.[3] The health economic modelling which underpin these recommendations are based 
on ‘what-if’ analyses/scenarios rather than empirical screening evidence[4] and this offers little 
insight on which diagnostic strategy is the most cost-effective.  
 
Decision makers, such as the National Institute for Health and Care Excellence (NICE), often rely on 
mathematical modelling to aid in decision making processes, as they are constantly faced with 
questions on what interventions should be funded. The purpose of modelling is to structure evidence 
on clinical and economic outcomes in a form that can be used to inform decisions on clinical practices 
and allocation of resources in order to achieve maximum benefits for health care.[5] Since the 
introduction of IGRAs, many studies have estimated the cost-effectiveness of various strategies for 
the diagnosis of LTBI using economic modelling in a decision analytical context. A previous clinical 
guideline [3] which included a systematic review highlighted that no published studies were identified 
in these high risk groups. Hence, in this review, the aim is to identify from recent literature the 
suitability of existing cost-effectiveness models that compared different diagnostic strategies for 
identifying LTBI in children, immunocompromised or at risk of immunosuppression and people from 
countries with a high incidence of TB. 
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Methods 
 
Study eligibility criteria 
 
Citations retrieved were screened by two reviewers (PA and AT) and included in the review if they 
met the following criteria: Children (immunocompetent), people who are immunocompromised or at 
risk from immunosuppression (e.g. transplant recipients or HIV) and recent arrivals from countries 
with a high incidence of TB (≥ 40 cases per 100,000), and comprising a formal economic evaluation 
involving direct comparison between IGRAs (QFT-G, QFT-GIT or T-SPOT.TB) and TST, and 
included a decision analytic model.  
 
Search strategy 
A search of the literature for published economic evaluations was performed for the purpose of 
identifying the suitability of existing cost-effectiveness models and their model design. 
 
The cost-effectiveness search was developed and conducted as part of a wider systematic review that 
aimed to compare both the clinical effectiveness and cost-effectiveness of screening tests (IGRAs and 
TST) for LTBI in high risk groups.[6] Electronic databases were searched, applying the search 
strategy to the following databases: MEDLINE, MEDLINE In-Process Citations and Daily Update, 
Embase, NHS Economic Evaluation Database (NHS EED), Health Economics Evaluation Database 
(HEED), Science Citation Index, Research Papers in Economics (RePEC) and Cost-effectiveness 
analysis (CEA) Registry. The search was limited to English language and studies published between 
2009 and June 2015. This time point was chosen because a clinical guideline [3] which included a 
systematic  review[3]  searched for studies published up to 2009, but did not identify any relevant 
economic modelling studies. Reference lists of potentially relevant articles were manually searched to 
identify additional studies. Details of search terms are presented in the Appendix. 
 
Study selection 
All citations retrieved were screened by two independent reviewers (PA and AT) at title/abstract level, 
of which potentially relevant publications were further examined for full text. Any disagreements 
between the reviewers were resolved by a consensus.  
 
Data extraction 
Data extraction was conducted by one reviewer (PA) and further cross-checked by a second reviewer 
(AT). Any disagreements were resolved by discussion or by recourse to a third party reviewer. 
Information was extracted on study details (title, author and year of study), baseline characteristics 
(population, intervention, comparator and outcomes), methods (study perspective, time horizon, 
discount rate, measure of effectiveness current, assumptions and analytical methods), results (study 
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parameters, base-case and sensitivity analysis results), discussion (study findings, limitations of the 
models and generalizability) and other (source of funding and conflicts of interests).  
 
 
 
Quality assessment 
The quality of the studies was assessed using the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS)[7] and the Philips’ checklist,[8] respectively. The CHEERS 
assessment tool comprises of six dimensions which include title and abstract, introduction, methods, 
results, discussion and other. The Philips’ quality assessment tool comprises of two main dimensions, 
structure of the model and data used to parameterized the model. Study quality was assessed by one 
reviewer (PA) and cross-checked by a second reviewer (AT).  
 
Data synthesis 
Information extracted from the included studies were summarised and presented in Table 1. These 
findings were compared narratively, and recommendations for the future modelling of LTBI are 
discussed. 
 
Results  
The literature search identified 8793 records through electronic database searches and other sources. 
After removing duplicates, 4020 records were screened for inclusion. On the basis of title and 
abstract, 3995 records were excluded. The remaining 25 records were included for full-text screening. 
A further 15 articles were excluded at the full-text stage, and the reasons for exclusion are shown in 
Figure 1. There were no disagreements between the two reviewers, hence the third-party reviewer was 
not required. The literature search identified ten studies that estimated cost-effectiveness of IGRAs 
compared with TST in diagnosing LTBI in our three populations of interest, and included a decision 
analytical model. 
 
Characteristics of included studies 
The characteristics of these models are summarised in Table 1. Four[9-12] economic evaluations were 
conducted in Japan, three[13-15] in the USA and two[3, 4] in the UK, and one[16] in South Africa. 
Three studies[9-11] compared QFT-GIT with TST, two[13, 14] compared IGRA with TST, but have 
not suggested the type of IGRA being used, one[15] compared QFT-G with TST and four[3, 4, 12, 
16] compared various testing strategies (TST, QFT, QFT-GIT, T-SPOT.TB, positive TST followed by 
QFT and positive TST followed by T-SPOT.TB).  A clinical guideline which included an economic 
model[3] included a no testing strategy. Two[10, 16] economic evaluation were conducted in a child 
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population, six[9, 11-15] in the immunocompromised population and two[3, 4] in the recently arrived 
population.  
 
Six[3, 9-13] studies reported results in terms of cost per quality-adjusted life year (QALY) gained, 
three studies[4, 15, 16] reported their results in terms of cost per life years saved (LYS), cost per false 
negative cases of LTBI avoided, cost per TB deaths avoided, cost per reactivation TB avoided or cost 
per TB avoided and one study[14] was based on number needed to screen to prevent one case of TB. 
From the base case results reported, IGRAs  tended to be less costly and more effective than other 
strategies (e.g. TST) in identifying LTBI in these high-risk populations 
 
All of the studies included a decision analytical model.  The health states included in the models 
represented those that people would experience while being screened for LTBI. In the model with 
children, the health states included healthy, LTBI, TB and dead. There was some variation in the 
health states for the immunocompromised population, due to differences in underlying disease. In the 
models with recently arrived people, the health states included test results, treatment for LTBI and 
treatment for TB. One[4] of the model structures was illegible in this population. 
 
Model time horizons ranged from one year to lifetime. In the models with children, the time horizon 
was lifetime (up to 80-years) with one-year cycle lengths. In the models with immunocompromised 
cohorts, the time horizons ranged from one-year to lifetime, with three-month or one-year cycle 
lengths and in the recently arrived cohort, the time horizons ranged from 15-years to 20-years, with 
annual cycle lengths. Authors suggested that their time horizons were long enough to measure the 
costs and benefits of these diagnostic strategies. All studies clearly stated and justified their time 
horizon, cycle lengths and discount rates, where appropriate. 
 
Resource use and costs depended on the perspective taken. All studies clearly stated the 
perspective/viewpoint of their analyses. Six studies[3, 4, 12, 14, 15] conducted their analyses from the 
UK NHS or other national health payer perspective, and the remaining four studies[9-11, 13] 
conducted their analyses from the societal perspective. The six models that presented results from a 
health payer perspective included direct costs related to the health service (cost of diagnostic tests, 
chest x-ray and sputum examinations, treatment for LTBI/ TB and treatment for INH-induced 
hepatotoxicity). From the four models that presented results based on the societal perspective, three 
models[9-11] have not included any indirect costs. 
 
Due to the uncertainty around model input parameters and assumptions made in the models, all 
authors conducted sensitivity analyses. Five studies[3, 4, 14-16] conducted deterministic (one- and 
two-way) sensitivity analyses alone. The remaining studies[9-13] conducted both deterministic and 
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PSAs. Sensitivity analyses were conducted around changing the prevalence of LTBI in these 
populations, test accuracies of diagnostic tests, cost of IGRAs, return rates for TST and varying the 
progression rate from LTBI to TB. 
 
Quality assessment of the modelling methods  
Structure 
The structure of the models were generally of good quality. Studies clearly stated decision problems 
and objectives of the model, perspective of the analysis and presented model structures which 
represented the clinical pathway people would follow while being screened for LTBI. However, there 
were structural concerns identified; three studies[9-11] have undertaken their analyses from the 
societal perspective, but have not included indirect costs (e.g. productivity loss) in the analyses. In 
general, studies stated the location of the analyses, but not their setting, and this may impact on the 
generalisability of results. Clear, illustrative model structures were presented in majority of the studies 
except in the Pareek et al. study, where the illustrative structure was illegible.  
 
All authors justified their choice of model structure, which represented the coherent theory of LTBI 
disease and its treatment. Six studies[9-13, 16] used decision tree structures with Markov nodes for 
their analyses, three studies[3, 4, 15] used decision tree structures alone and one study[14] used a 
Markov model alone. The guideline[3] which comprised of an economic evaluation included a 
proportion of people returning to have their TST result read. One study[15] included a proportion of 
people with indeterminate test results on an IGRA, and assumed that people received a second IGRA 
immediately, but this was not shown in the illustrative structure. All studies included chest x-ray 
and/or sputum examination to confirm initial active symptomatic TB. All studies included cost of 
treatment for LTBI/TB. As a result of adhering to treatment, all studies included a proportion of 
people developing Isoniazid (INH)-induced hepatotoxicity. Other adverse events were not considered. 
In the Markov models, similar health states were used to simulate the natural history of LTBI over 
time.  
 
Data 
Methods used to identify information to populate the models were satisfactory. Studies[3, 4, 9, 10, 12-
16] conducted literature reviews, but have not specified the aim of the review. All [3, 4, 9-16] studies 
provided references for their model inputs, but were not clear on the choices between data sources or 
the quality of information used in the models. This might have been a result of a paucity of 
information in the literature. 
Most models[9-16] used published sources to obtain or derive an estimate of the prevalence of LTBI, 
but some studies[9, 11, 13, 15] have not elaborated on what the prevalence represents (e.g. prevalence 
of LTBI in contact tracing, prevalence of LTBI based on occasional screening in the population of 
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interest or prevalence of LTBI that would develop to active TB). Additionally, studies[11-13, 15, 16] 
using multiple sources were not transparent on the methods to derive the prevalence of LTBI. Test 
performance for TST and IGRAs were required for the models. Most studies[11-13, 15, 16] conducted 
literature reviews, and have elaborated on the methods to derive an estimate of sensitivity and 
specificity. Methods included calculating an estimate based on an average of sensitivity/specificity 
obtained from the literature and obtaining estimates from meta-analyses. All costs required for the 
models have been referenced, and where applicable, inflated using the appropriate indices. Authors 
clearly stated the unit costs used in the models, but some[9-11, 13] authors have not elaborated on the 
resource used to estimate the unit costs, especially for the treatment of TB. The perspective of the 
analyses was stated, but in some studies[9-11], the costs did not reflect the viewpoint of the analyses. 
All authors[4, 9-14, 16], where necessary, discounted costs and benefits using the appropriate rates. 
Where results were reported in terms of QALYs, authors[3, 9-13] provided references used to obtain 
the utility weights, but have not elaborated on if the source of utility information was relevant to their 
population. 
 
Uncertainty and assumptions 
Uncertainty is unavoidable in economic modelling. Briggs and Gray 1999[17] and Philips et al.[8] 
have suggested methods to handle uncertainty. All models have undertaken univariate and 
multivariate sensitivity analysis on key model input parameters. Four studies[9-12] have also 
undertaken probabilistic sensitivity analysis (PSA) for joint parameter uncertainty.  In order to have a 
workable model structure, most studies clearly stated their simplifying assumptions, except the model 
developed by Kowada 2014; these assumptions were unclear. In general, assumptions outlined 
appeared to be feasible, but strong in some studies[3, 4, 9]. In the NICE study,[3] authors assumed 
that people adhered to treatment of LTBI/TB, and it would not lead to any adverse events. Pareek et 
al.[4] assumed that testing with an IGRA would not lead to an indeterminate result. Kowada 2010[9] 
assumed that the chest x-ray is 100% sensitive and specific for diagnosing TB.  
 
Summary of the general approaches to modelling LTBI 
Children  
Kowada 2012[10] 
Kowada 2012 estimated the cost-effectiveness of QFT-GIT compared with TST or chest x-ray for the 
diagnosis of LTBI in children, using a decision tree structure with Markov nodes. The model started 
with a hypothetical cohort of children receiving one of three diagnostic strategies and continued with 
them occupying the LTBI/initial TB or no LTBI health state, characterised by the prevalence of the 
disease. On positive results, children received a chest x-ray to confirm TB. Children who received a 
negative result on the chest x-ray were treated for LTBI. Estimates of sensitivity and specificity of 
tests were obtained from a meta-analysis of developed-country studies. The analysis was conducted 
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from the societal perspective and base-case results were expressed as an incremental cost-
effectiveness ratio (ICER) based on the outcome of cost per QALY gained. Kowada conducted one- 
and two-way sensitivity analyses and PSA. The base case results demonstrated that QFT-GIT alone 
was less costly and more effective than TST alone.  
 
Mandalakas 2013[16] 
Mandalakas and colleagues used a decision tree structure with Markov nodes to model young 
household contacts with an index case. The model started with children (< 5 years) who received one 
of five diagnostic strategies (no test, TST alone, IGRA alone, TST positive followed by IGRA and 
TST negative followed by IGRA). Children with positive test results were eligible for treatment for 
LTBI. Children entered the model at the LTBI health state, and could progress to no infection, initial 
infection, subsequent infection due to future exposures, pulmonary TB, disseminated TB, TB death or 
death from other causes. The analysis was conducted from the third-party payer and societal 
perspectives, and the main results were reported in terms of cost per life-year saved (LYS). Base case 
results indicated that for 0-2 year olds, the no testing strategy was the dominant strategy whilst for 3-5 
year olds, an IGRA following a negative TST was the most effective strategy but not cost-effective 
compared to no testing.  
 
Immunocompromised 
Kowada 2010[9] 
Kowada used a decision tree structure with Markov nodes to assess cost-effectiveness of QFT-GIT 
versus TST in people with rheumatoid arthritis, over a lifetime horizon, starting with a cohort aged 40 
years. People with positive/negative results on the TST or positive QFT-GIT received a chest x-ray to 
diagnose TB, which was assumed to be 100% sensitive and specific. The author provided no 
comment/discussion on the sources of prevalence of LTBI in this population.  Information on the 
sensitivity and specificity were obtained from a meta-analysis. The primary outcome measure of 
effectiveness was QALYs gained. The analysis was conducted from the societal perspective and 
results presented as cost per QALY gained. Kowada conducted one-way and two-way sensitivity 
analyses and PSA, but the distributions used were not presented. QFT-GIT alone was found to be the 
most cost-effective strategy, and the base-case results were robust to changes in model input 
parameters. Kowada suggested that results from the PSA showed that IGRA was the preferred option 
with 100% probability of being cost-effective compared to TST at a willingness-to-pay of US$50,000 
per QALY. 
  
Kowada 2013[11] 
Kowada used a decision tree structure with Markov nodes to assess QFT-GIT, TST or chest x-ray in 
people being screened before haemodialysis, over a lifetime horizon. People with positive results on 
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TST/QFT-GIT received a chest x-ray to detect TB, and were treated accordingly for TB/LTBI. The 
author assumed that chest x-ray was 100% sensitive and specific. The author conducted a review of 
the literature, but it was unclear on how the accuracy of the tests were derived. The primary outcome 
measure of effectiveness was QALYs gained, however, the author has not elaborated on the 
descriptive tools used to value these health states. The analysis was conducted from the societal 
perspective and results presented in terms of costs per QALY gained. Kowada conducted one- and 
two-way sensitivity analyses and PSA, but the distributions and the cost-effectiveness acceptability 
curve were not presented. The author demonstrated that QFT-GIT alone was the most cost-effective 
strategy for the diagnosis of LTBI. 
 
Kowada 2014[12] 
Kowada used a decision tree structure with Markov nodes and estimated the cost-effectiveness of 
IGRAs versus TST in HIV positive pregnant women in low incidence of TB countries. The model 
simulated the pathway of four cohorts (BCG-vaccinate during pregnancy, non-BCG vaccinated during 
pregnancy, BCG vaccinated postpartum period, and non-BCG vaccinated postpartum period), 
separately, and the cost-effectiveness was estimated over a thirty-year time horizon. The starting point 
of the model was women aged 20 years who received one of five (TST alone, QFT-G alone, T-SPOT 
alone, TST positive followed by QFT or TST positive followed by T-SPOT.TB) testing strategies. 
TST was considered positive if the induration was ≥5mm and ≥10mm in those who were non-BCG 
vaccinated and BCG-vaccinated, respectively. Women with positive TST, QFT-G or T-SPOT.TB 
strategies received a chest x-ray to diagnose TB. In the combination strategies, women who received a 
positive TST result then received QFT-G or T-SPOT.TB, and if positive, received a chest x-ray to 
diagnose TB. The analysis was conducted from the public health payer perspective and results 
presented in terms of cost per QALYs gained. Kowada conducted PSA, and one- and two-way 
sensitivity analyses. Base-case results showed that positive TST followed by QFT-G was the most 
cost-effective strategy for occasional screening of women who were non-BCG vaccinated during 
pregnancy. Results from the PSA showed that the TST followed by QFT-G strategy was the preferred 
option with 100% probability of being cost-effective at all willingness-to-pay values considered. The 
results from the sensitivity analyses showed that the base case results were sensitive to changes in the 
sensitivity of T-SPOT.TB, and the sensitivity of QFT-G in non-BCG vaccinated women.  
 
Laskin et al., 2013[13] 
Laskin and colleagues used a decision tree structure with Markov nodes to determine the most cost-
effective screening strategy in children with new-onset idiopathic nephrotic syndrome. The model 
starts with children receiving TST/IGRA, and if positive children were eligible for LTBI treatment. 
The authors assumed that effective LTBI treatment provided long-term protection against LTBI/TB. 
The analyses were conducted from the societal perspective and included indirect costs on travel time 
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and loss of productivity. Base-case results showed that the no screen strategy was less costly and more 
effective than other strategies. Results from this study should be interpreted with caution because the 
discounted and undiscounted costs were similar despite the cost-effectiveness being measured over a 
lifetime horizon. Results were sensitive to changes in the prevalence of LTBI in this population, with 
the questionnaire followed by IGRA screening strategy to be the most cost-effective strategy at a 
prevalence of >4.9%. Results from the PSA showed that at a prevalence of 1.1%, no screening 
compared with IGRA was the preferred screening option, but the authors have not stated at what 
willingness-to-pay value.  
 
Linas et al., 2011[14] 
Linas and colleagues constructed a decision tree structure with Markov nodes and estimated the cost-
effectiveness of using TST compared with IGRAs in various populations. The model began with a 
cohort receiving one of three diagnostic strategies (TST alone, IGRA alone or no screening), and 
continued with people characterised by their disease status (LTBI/no LTBI). People with positive 
IGRA/TST received treatment for LTBI. Costs related to a health service perspective were obtained 
from published sources. Utility values estimated were based on the SF-36 and EQ-5D descriptive 
systems. The primary outcome was cost per QALY gained over a lifetime horizon. Base-case results 
showed that in the HIV-infected cohort, screening with IGRA alone was marginally more costly and 
effective than the no screening option with an ICER of $12,800. People who were on 
immunosuppressive medication, the reported ICER for TST compared with no screening was 
$129,000. Sensitivity analysis results showed that increasing the mean age to 65 years, TST remained 
cost-effective in people living with HIV. Base-case results were sensitive to changes to the estimates 
on health-related quality of life for people who received treatment for TB. Screening with TST or 
IGRA resulted in ICERs greater than $100,000 for people with diabetes or end-stage renal disease. 
 
Swaminath et al., 2013[15] 
Swaminath and colleagues used a decision tree structure and compared QFT-G with TST in people 
with inflammatory bowel disease. The model simulated people with moderate to severe active Crohn's 
disease being treated with immunosuppressive medication. On positive results, people received 
treatment for LTBI. Swaminath et al. suggested that people with indeterminate results on the QFT-G 
would immediately receive a second QFT-G test. However, this pathway was not shown in the 
decision tree structure. The prevalence of LTBI in this population was obtained from World Health 
Organization. Sensitivity and specificity of tests were derived based on information obtained from 
published sources, and not based on a systematic review. The analysis was conducted from the health 
payer perspective and results presented in terms of costs per false negative case avoided, TB 
reactivations and deaths avoided. The authors conducted one-way sensitivity analyses around input 
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parameters. Swaminath and colleagues concluded that QFT-G was less costly and more effective than 
the TST in this population. 
 
Recently arrived 
Pareek et al., 2013[4] 
Pareek and colleagues used a decision tree structure and compared T-SPOT.TB, QFT-GIT, TST 
positive plus confirmatory T-SPOT.TB or TST positive plus confirmatory QFT-GIT for screening 
immigrants for LTBI. The illustrative model structure presented in the supplementary appendix was 
illegible. The authors suggested that immigrants who were symptomatic at screening or had a positive 
IGRA/TST result were referred for a chest x-ray and further clinically assessed. Immigrants with 
positive IGRA and/or positive TST result and normal chest x-ray without any symptoms of suggesting 
TB were considered to have LTBI. For a positive TST, cut-offs of ≥6mm and ≥15mm were used for 
BCG-unvaccinated and BCG-vaccinated participants, respectively. Additionally, the authors used a 
non-stratified cut-off of ≥10mm to suggest a positive TST. Information required to populate the model 
were obtained from an observational study undertaken by the authors and from published sources. 
Study participants included recently arrived (≤ 5 years) immigrants to the UK aged ≥ 16 years (with 
symptoms of TB) or from a country with a high incidence of TB. Information on the prevalence of 
LTBI was derived from immigrants aged ≤35 years that had been tested with the three screening tests. 
The analysis was undertaken from the UK NHS perspective in a primary care setting. The outcome 
measures included in the analyses were the number of cases of TB avoided and the number of LTBI 
cases needed to be treated to prevent one case of TB over a 20-year time horizon. Base-case results 
showed that the screening strategy no port-of-entry chest x-ray and screening with QFT-GIT was 
cost-effective with an ICER of approximately £21,600 per case of TB avoided and the no port-of-
entry chest x-ray and screening with one-step QFT-GIT was cost-effective, with an ICER of 
approximately £31,900 per case of TB avoided. These strategies were cost-effective in immigrants 
whose country of origin had an incidence of TB of 250 per 100,000 and 150 per 100,000, 
respectively. Sensitivity analyses results showed that increasing the prevalence and progression rate 
from LTBI to TB increased the cost-effectiveness of using the QFT-GIT. Reducing specificity 
resulted in the T-SPOT.TB becoming the most cost-effective strategy. Reducing the proportion of 
immigrants accepting and adhering to LTBI treatment lead to higher cost-effectiveness estimates.  
 
CG117[3] 
The authors of CG117 used a decision tree structure and compared four testing strategies: TST, 
IGRA, TST followed by IGRA for people with positive results and no test, in immigrants from 
countries with a high incidence of TB. In the TST/IGRA strategies, people who received a positive 
result were treated for LTBI. Conversely, people with negative results, a proportion were given BCG-
vaccination. In the combination strategy, people who tested positive on the TST received a QFT test. 
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Immigrants with positive QFT results were treated for LTBI, and those with negative results, a 
proportion were given a BCG vaccination. The end-point of the model is people developing TB 
having received a BCG vaccination or treatment for LTBI. Sensitivity of tests were derived based on 
values obtained from two publications. Costs included in the model were those related to the UK NHS 
and Personal Social Services (PSS), and were presented in UK pounds sterling in 2008/09 prices. 
Costs obtained from published sources were inflated using the Hospital and Community Health 
Services Pay and Price Index. The results showed that positive TST followed by IGRA, and IGRA 
alone strategies were associated with ICERs below £30,000 per QALY compared with no testing 
strategy. Results from the sensitivity analyses showed that varying the cost of an IGRA (£50 to £60) 
changed the direction of the cost-effectiveness results.
Table 1. Summary characteristics of the models used to compare IGRAs and TST in identifying LTBI in children, immunocompromised and recently arrived 
immigrants 
Study ID 
(First author, year, 
and country) 
Aim of the study Study 
characteristics 
(study design, 
perspective, 
setting 
Intervention Outcome(s) Model type Health states  Results (base case 
and sensitivity 
analysis) 
Children 
Kowada 2012,[10] 
Japan 
To assess the cost-
effectiveness of 
school-based TB 
screening using 
QFT-GIT versus 
the TST and CXR 
Cost-
effectiveness 
analysis, societal 
perspective, 
setting not 
reported 
QFT-GIT Cost per QALY Decision tree 
structure to model 
the short term 
events followed 
by a Markov 
modelling 
structure 
Healthy, LTBI, 
TB and dead 
QFT-GIT was less 
costly and more 
effective than TST 
strategy 
Mandalakas 2013,[16] 
South Africa  
To estimate the 
health and 
economic 
outcomes of five 
TB screening 
strategies  
Cost-
effectiveness 
analysis, third 
party payer and 
societal 
perspectives 
IGRA (QFT, T-
SPOT.TB) 
Cost per LYS Decision tree 
structure to model 
the short term 
events followed 
by a Markov 
modelling 
structure 
LTBI health 
state, and could 
progress to no 
infection, 
initial 
infection, 
subsequent 
infection due to 
future 
exposures, 
pulmonary TB, 
disseminated 
TB, TB death 
and death from 
other causes 
In the 0-2 cohort, 
no testing strategy 
dominated other 
strategies 
In the 0-3 cohort, 
the TST –ve 
followed by IGRA 
was the most - 
effective with a 
reported ICER of 
approximately 
US$233 000 per 
LYS versus no 
testing 
Immunocompromised 
Kowada 2010,[9] 
Japan 
To assess the cost-
effectiveness of 
QFT-GIT versus 
TST for TB 
screening of RA 
patients prior to 
Cost-
effectiveness 
analysis, societal 
perspective, 
setting not 
reported 
QFT-GIT Cost per QALY Decision tree 
model with 
Markov nodes  
No LTBI, 
LTBI, TB and 
death 
QFT-GIT was less 
costly and more 
effective than TST 
strategy. At 
society’s WTP per 
QALY, the 
probability of QFT-
15 
 
Study ID 
(First author, year, 
and country) 
Aim of the study Study 
characteristics 
(study design, 
perspective, 
setting 
Intervention Outcome(s) Model type Health states  Results (base case 
and sensitivity 
analysis) 
initiation of TNFα 
antagonist therapy 
GIT testing strategy 
has a 100% 
probability of being 
cost-effective 
compared to the 
TST 
Kowada 2013,[11] 
Japan 
To assess the cost-
effectiveness of 
QFT-GIT 
compared with the 
TST and the CXR 
for TB screening 
of haemodialysis 
Cost-
effectiveness, 
societal 
perspective, 
setting not 
reported 
QFT-GIT Cost per QALY Decision tree 
model with 
Markov nodes  
Maintenance 
dialysis with 
no disorder, 
maintenance 
dialysis with 
LTBI, 
maintenance 
dialysis with 
TB and death 
QFT-GIT was 
dominant compared 
to TST testing 
strategy. Results 
from the SA 
showed that the 
base-case results 
were sensitive to 
the BCG 
vaccination rate. At 
society’s WTP per 
QALY, the 
probability of QFT-
GIT testing strategy 
has a 100% 
probability of being 
cost-effective 
compared to the 
TST 
Kowada 2014,[12] 
Japan 
To assess the cost 
effectiveness for 
TB screening of 
high risk HIV 
positive pregnant 
women by using 
IGRAs compared 
to the TST in low 
Cost-
effectiveness 
analysis, health 
service 
perspective, low 
incidence of TB 
country, but 
setting not 
reported 
1) TST alone, 2) 
QFT alone, 3) T-
SPOT.TB, 4) 
TST followed by 
QFT and 5) TST 
followed by T-
SPOT.TB 
Cost per QALY Decision tree 
model with 
Markov nodes  
Non-LTBI and 
non-TB, LTBI, 
non MDR-TB, 
MDR-TB and 
dead 
Base-case results 
showed that the T-
SPOT.TB is less 
costly and was 
more effective 
compared to other 
strategies. SA 
showed that the 
cost-effectiveness 
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Study ID 
(First author, year, 
and country) 
Aim of the study Study 
characteristics 
(study design, 
perspective, 
setting 
Intervention Outcome(s) Model type Health states  Results (base case 
and sensitivity 
analysis) 
incidence 
countries 
was sensitive to the 
sensitivity of T-
SPOT.TB, the 
sensitivity of QFT, 
specificity of T-
SPOT.TB and the 
specificity of QFT 
in close contacts  
Laskin 2013,[13] USA To determine the 
most cost-effective 
LTBI screening 
strategy before 
long-term steroid 
therapy in a child 
with new-onset 
idiopathic 
nephrotic 
syndrome 
Cost-
effectiveness 
analysis, societal 
perspective, 
setting not 
reported 
IGRAs Cost per QALY Decision tree 
structure to model 
the short term 
events followed 
by a Markov 
modelling 
structure  
Well, LTBI, 
TB, nephrotic 
relapse and 
dead) for the 
longer-term 
events 
Base-case results 
showed that IGRA 
was less costly and 
produced 
moderately more 
QALYs compared 
to universal TST 
Linas 2011,[14] USA To estimate the 
cost-effectiveness 
of LTBI screening 
using the TST and 
IGRAs 
Cost-
effectiveness 
analysis, health 
service, setting 
not reported 
IGRAs and TST Number needed to 
screen to prevent 
one case of active 
TB, life 
expectancy, 
quality-adjusted 
life expectancy 
Markov model LTBI with 
INH, LTBI no 
INH, INH 
related 
hepatitis, < six 
months INH, 
6-8 months 
INH, nine 
months INH, 
Active TB, 
post active TB 
and death 
Base-case results 
showed that people 
who are taking 
immunosuppressive 
medications, TST 
screen was not 
likely to be cost-
effective to the no 
screening strategy. 
Similar results were 
reported for people 
with ESRD 
Swaminath 2013,[15] 
USA 
To compare the 
performance of 
TST and QFT-G 
Cost-
effectiveness, 
health care payer, 
QFT-G Cost per false 
negative cases of 
LTBI avoided, cost 
Decision tree 
model 
True positive, 
true negative, 
false positive, 
Base-case results 
showed that QFT-G 
dominated the TST 
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Study ID 
(First author, year, 
and country) 
Aim of the study Study 
characteristics 
(study design, 
perspective, 
setting 
Intervention Outcome(s) Model type Health states  Results (base case 
and sensitivity 
analysis) 
got screening 
LTBI among 
immunosuppressed 
IBD patients based 
on prevalence, 
mortality risk 
reactivation TB, 
and costs 
setting not 
reported 
per TB deaths 
avoided, cost per 
reactivation TB 
avoided (this can 
be derived from the 
information 
provided) 
false negative, 
hepatitis, 
survive/death 
hepatitis  
strategy. 
Additionally, the 
use of QFT-G 
would avoid 30 
false-negative 
cases, 4.92 TB 
reactivations and 
1.4 deaths 
compared with TST 
Recently arrived 
CG117,[3] UK To compare the 
cost and effects of 
four strategies of 
testing for people 
suspected with 
LTBI in England 
and Wales  
Cost-
effectiveness 
analysis, NHS 
and Personal 
Social Services 
(PSS) 
1) TST, 2) 
IGRA, 3) TST 
followed by 
IGRA for people 
with positive 
TST and 4) no 
test (to inform 
and advise only)  
Cost per QALY Decision tree 
model 
Test results, 
treatment for 
LTBI, 
treatment for 
TB 
Results showed that 
TST +ve followed 
by IGRA and 
IGRA testing 
strategies were 
associated with 
ICERs below £30, 
000 per QALY 
compared with no 
testing. The results 
from the sensitivity 
analyses showed 
that varying the 
cost of an IGRA 
(£50 to £60) 
changes the 
direction of the 
cost-effectiveness 
results 
Pareek 2013,[4] UK To assess the cost-
effectiveness of 
LTBI screening 
using different 
Cost-
effectiveness 
analysis, NHS, 
1) T-SPOT.TB 
alone, 2) QFT-
GIT alone, 3) 
TST plus 
Cost per case of 
active TB avoided 
Decision tree 
model 
The illustrative 
modelling 
structure was 
presented in a 
Results showed that 
screening of newly 
arrived immigrants 
from countries of 
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Study ID 
(First author, year, 
and country) 
Aim of the study Study 
characteristics 
(study design, 
perspective, 
setting 
Intervention Outcome(s) Model type Health states  Results (base case 
and sensitivity 
analysis) 
screening 
modalities at 
different incidence 
thresholds in a 
primary care 
setting, with and 
without CXR 
screening on 
arrival at port of 
entry 
primary care 
setting 
confirmatory T-
SPOT.TB (if 
TST positive), 
and 4) TST plus 
confirmatory 
QFT-GIT (if 
TST positive) 
supplementary 
web-appendix, 
but 
unfortunately, 
these structures 
were illegible 
origin with 
moderate (not 
defined) TB 
incidence is likely 
to be cost-effective 
by the use of one-
step IGRA testing 
compared to other 
screening strategies 
BCG, Bacillus Calmette–Guérin; CXR, Chest x-ray, ESRD, End-stage renal disease; HIV, Human immunodeficiency virus; IGRA, Interferon-gamma release assay; INH, 
Isoniazid; LTBI, Latent tuberculosis infection; NHS, National Health Service; PSS, Personal Social Services; QALY, Quality adjusted life-years, QFT-G, QuantiFERON-
Gold; QFT-GIT, QuantiFERON Gold-In-Tube; RA, Rheumatoid arthritis; SA, Sensitivity analysis; TB, Tuberculosis; TST, Tuberculin skin test; WTP, Willingness-to-pay 
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Discussion 
The evidence-base here offers some insight on the model structures which have been used to assess 
the cost-effectiveness of IGRAs compared with TST for the diagnosis of LTBI in high risk 
populations. We identified ten model-based economic evaluations, which mainly used decision tree 
structures with Markov nodes to simulate people being tested for LTBI, with majority of these models 
in the immunocompromised population. These results highlight that the evidence available for the 
other two populations is sparse.  
 
We appraised models against frameworks on best practice for reporting an economic evaluation and 
economic modelling. In general, all models performed well in terms of reporting quality, and add to 
existing cost-effectiveness literature, but are subject to limitations. First, majority of the studies 
indicated the location of the study but have not stated the setting of the analysis and this may limit the 
generalisability of the results. Second, a majority of the studies used QALYs as their outcome 
measure and have referenced the source of their utility values, but have not provided commentary on 
the descriptive tools used to value these health states. When obtaining health state utility values from 
the literature it is important to consider the methods/tools used to generate these values and their 
relevance to the population to which they are going to be applied. Third, the perspective of the 
analysis was stated in all studies, however, some of the resource use and costs reported did not reflect 
studies’ viewpoint. Fourth, studies were transparent about the methods to identify information to 
populate the models, but it was unclear on any assessment used on the quality of the information. 
Finally, all models have explored uncertainty around key model input parameters, but no attempt was 
made to explore methodological and structural uncertainty, or generalisability. Other concerns relate 
to the derivation of prevalence, test accuracy and transition probabilities; most studies have not 
elaborated on these statistical/pre-model analyses. 
 
We identified one study[18] that provided a review of the cost-utility studies available up to 2014 on 
the use of IGRAs compared with TST for the diagnosis of LTBI. The results of all studies included in 
the review were presented in terms of ‘cost per QALY.’ Though useful, other forms of economic 
evaluation studies, more specifically cost-effectiveness analyses, may provide relevant information on 
prevalence of LTBI or resource use and costs, for example. Studies presenting results in terms of cost 
per QALY alone may suggest that QALY is likely to capture all the benefits of identifying people 
with LTBI. The authors concluded that screening with TST for LTBI in an HIV population is cost-
effective, and screening with an IGRA within an immigrant population is moderately cost-effective.  
We identified a second systematic review[19] which focussed on the key model input parameters and 
the methodological differences in studies that assessed the cost-effectiveness of preventative treatment 
for TB in high risk populations, and not of LTBI diagnosis. In addition, economic models used to 
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assess the cost-effectiveness of strategies for identifying LTBI in a child population were not 
considered.  These authors have outlined the limitations identified in the studies, but have not 
undertaken a formal quality appraisal of the economic models against the CHEERS [7] or Phillips et 
al. [8] checklists. Our current review identifies and appraises the economic models that have been 
used to inform on the diagnosis of LTBI in high risk populations. 
 
For future advances in using economic models to aid in the decision making process for the most cost- 
effective strategy for identifying LTBI in high risk populations, analysts should consider the 
information required on prevalence of LTBI in these populations, diagnostic accuracy of test(s), and 
the illustrative model structure. Based on the studies identified, the methods used to derive 
prevalence, and sensitivity and specificity may not have provided the best estimates, and in some 
cases might have under/overestimated these input values. As no ‘gold standard’ test exists for LTBI 
diagnosis, estimates can be derived from meta-analysing studies that followed-up a cohort of people 
to the incidence of TB following testing with TST and/or IGRA. For this instance, best estimates 
would be based on the development of TB as a 'reference standard' for diagnosing LTBI. This method, 
as opposed to using exposure to TB and test agreement studies alone, may be more appropriate for use 
in decision analytical models. However, other points ought to be considered: serial testing, BCG 
vaccination history and anti-tuberculous treatment on testing positive, all of which can have an impact 
on evaluating test performance. Further discussion of these points are beyond the scope of this paper, 
but will be addressed in a subsequent manuscript.  
 
The models available provide insight on the clinical pathway should screening for LTBI be 
undertaken, and which strategy is likely to be cost-effective in high-risk populations. In future models, 
it will be important to consider which diagnostic strategy is most likely to be cost effective to identify 
LTBI that progresses to active TB; and not sensitivity and specificity of diagnostic tests aimed at 
identifying LTBI in general. Such models would incorporate a decision tree structure and 
epidemiological model to estimate the cost-effectiveness. These models would also provide useful 
information on an estimate of the number of people who are treated/untreated for LTBI and further 
developed TB, and any new cases of LTBI.  
 
We undertook a search of the literature to identify all relevant studies that compared TST and IGRAs 
for identifying LTBI in these three populations of interest. The main strength of this current review is 
the comprehensive search, reporting quality assessment and data extraction of the relevant 
information from these studies. Second, it provides a detailed overview and critique of the health 
economic models that have been used to estimate the cost-effectiveness of IGRAs compared with 
TST. In terms of limitations, some studies have not reported/presented information on model 
structure, how prevalence was derived; hence we could not provide a narrative for these studies.  
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Conclusion  
This review highlights the health economic models available on the cost–effectiveness of diagnosing 
LTBI in high risk populations. The majority of the models were undertaken in an 
immunocompromised population, which suggests that there is a paucity of evidence available in a 
child population and recent arrivals population. In general, all models performed well in terms of 
defining the decision problem, including the study perspective, outlining the choice of comparators, 
presenting an illustrative model structure and providing a clear outline of the assumptions.  
 
The evidence shows that the models available are based on identifying LTBI in general, and little is 
known about the cost-effectiveness of diagnostic tests that identify LTBI that progresses to active TB; 
which shows that research in this area is static. We propose that future pre-model analyses should 
consider deriving estimates based on the development of TB as a 'reference standard' for diagnosing 
LTBI in order to inform an economic model. However, the challenge/practicality is to identify 
prospective longitudinal studies with adequate sample size and a lengthy follow-up in people at high 
risk of developing TB. 
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Appendix  
 
Example search strategy 
This search was developed and conducted as part of a wider systematic review that aimed to compare 
both the clinical effectiveness and cost-effectiveness of screening tests (IGRAs and TST) for LTBI in 
high risk groups.[1] It was updated in Dec 2014 and June 2015 
 
Ovid MEDLINE(R) 1946 to March Week 2 2014, searched on 21/03/2014  
1 (laten* adj3 (tb* or tubercul*)).tw. 2701 
2 ltb*.tw. 6939 
3 tubercul*.tw. 158617 
4 Tuberculosis/ 51049 
5 Latent Tuberculosis/ 866 
6 Tuberculosis, Pulmonary/ 63874 
7 Mycobacterium tuberculosis/ 35401 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 195420 
9 quantiferon*.tw. 819 
10 QFT*.tw. 557 
11 t spot*.tw. 261 
12 exp Enzyme-Linked Immunosorbent Assay/ 122317 
13 Interferon-gamma Release Tests/ 377 
14 ((interferon* or IFN*) adj3 gamma* adj3 (release* or test* or assay*)).tw. 3856 
15 ((y-interferon or interferon-y) adj3 (release* or test* or assay*)).tw. 7 
16 IGRA*.tw. 448 
17 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 126231 
18 8 and 17 3837 
19 Latent Tuberculosis/di 576 
20 18 or 19 4058 
21 Animals/ not Humans/ 3812070 
22 20 not 21 3477 
23 limit 22 to english language 3011 
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24 limit 23 to ed=20091207-20140321 1285 
 
